The IARC TP53 database: New online mutation analysis and recommendations to users

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999

Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome

Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899

Database of p53 gene somatic mutations in human tumors and cell lines.

Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858

Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73

Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241

p53 gene mutation: software and database

Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185

p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.

Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180

p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer

Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164

p53 and the Li-Fraumeni syndrome

Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153

p53 gene mutation: software and database

Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

Bamford, S., Dawson, E., Forbes, S. A., Clements, J., Pettett, R., Doǧan, A., Flanagan, A. M., Teague, J. W., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,248

Small-cell lung cancer

van Meerbeeck, J. P., Fennell, D. A., & Ruysscher, D. D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,239

p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes

Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R. D., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.068 · Cited by 1,135

mCSM: Predicting the effects of mutations in proteins using graph-based signatures

Pires, D. E. V., Ascher, D. B., & Blundell, T. L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt691 · Cited by 1,066

Principles of Tumor Suppression

Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,028

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884

Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

Kato, S., Han, S., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 895

p53: 800 million years of evolution and 40 years of discovery

Levine, A. J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 876

Mutations induced by ultraviolet light

Pfeifer, G. P., You, Y., & Nia, A. B. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.06.057 · Cited by 798

Improving the Assessment of the Outcome of Nonsynonymous SNVs with a Consensus Deleteriousness Score, Condel

González-Pérez, A., & López-Bigas, N. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.03.004 · Cited by 772

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 760

PDL1 Regulation by p53 via miR-34

Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683

BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma

Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., Berghmans, S., Mayhall, E. A., Traver, D. J., Fletcher, C. D. �., et al. (2005) · Current Biology · doi:10.1016/j.cub.2005.01.031 · Cited by 684

Chemical basis of inflammation-induced carcinogenesis

Ohshima, H., Tatemichi, M., & Sawa, T. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00283-2 · Cited by 623

RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators

Harris, R. S., Petersen‐Mahrt, S. K., & Neuberger, M. S. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00742-6 · Cited by 609

Aristolochic acid and the etiology of endemic (Balkan) nephropathy

Grollman, A. P., Shibutani, S., Moriya, M., Miller, F. W., Wu, L., Moll, U. M., Suzuki, N., Fernandes, A., Rosenquist, T. A., Medverec, Z., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701248104 · Cited by 603

tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors

Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D. S., Kutok, J. L., Fletcher, C. D. �., Morris, J. P., Liu, T. X., Schulte‐Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 607

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592

Transcriptional Regulation by P53

Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569

Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data

Cooper, G. M., & Shendure, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3046 · Cited by 593

Control of Cell Proliferation and Apoptosis by Mob as Tumor Suppressor, Mats

Lai, Z.-C., Wei, X., Shimizu, T., Ramos, E., Rohrbaugh, M., Nikolaidis, N., Ho, L., & Li, Y. (2005) · Cell · doi:10.1016/j.cell.2004.12.036 · Cited by 595

The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors

Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543

Small-cell lung cancer

Jackman, D. M., & Johnson, B. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67569-1 · Cited by 504

Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth

Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.56 · Cited by 492

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort

Mai, P. L., Best, A. F., Peters, J. A., DeCastro, R. M., Khincha, P. P., Loud, J. T., Bremer, R. C., Rosenberg, P. S., & Savage, S. A. (2016) · Cancer · doi:10.1002/cncr.30248 · Cited by 487

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. L., & Eeles, R. A. (2003) · PubMed · Cited by 480

Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer

Klein, C. A., Blankenstein, T. J. F., Schmidt‐Kittler, O., Petronio, M., Polzer, B. M., Stoecklein, N. H., & Riethmüller, G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09838-0 · Cited by 479

Gallbladder cancer: lessons from a rare tumour

Wistuba, I. I., & Gazdar, A. F. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1429 · Cited by 453

Small Cell Lung Cancer

Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0011 · Cited by 444

Structure–function–rescue: the diverse nature of common p53 cancer mutants

Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 442

Familial gastric cancer: genetic susceptibility, pathology, and implications for management

Oliveíra, C., Pinheiro, H. C., Figueiredo, J., Seruca, R., & Carneiro, F. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71016-2 · Cited by 427

Structural Basis of DNA Recognition by p53 Tetramers

Kitayner, M., Rozenberg, H., Kessler, N., Rabinovich, D., Shaulov, L., Haran, T. E., & Shakked, Z. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.015 · Cited by 408

Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study

Villani, A., Tabori, U. Y., Schiffman, J. D., Shlien, A., Beyene, J., Druker, H. A., Novokmet, A., Finlay, J. L., & Malkin, D. M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70119-x · Cited by 420

Aristolochic acid-associated urothelial cancer in Taiwan

Chen, C., Dickman, K. G., Moriya, M., Zavadil, J., Sidorenko, V. S., Edwards, K. L., Gnatenko, D. V., Wu, L., Turesky, R. J., Wu, X., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119920109 · Cited by 418

Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severityPreprint

Stone, E. A., & Sidow, A. (2005) · Genome Research · doi:10.1101/gr.3804205 · Cited by 410

TP53 Mutations in Nonsmall Cell Lung Cancer

Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 404

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 398

Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification

Röwert‐Huber, J., Patel, M. J., Forschner, T., Ulrich, C., Eberle, J., Kerl, H., Sterry, W., & Stockfleth, E. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07860.x · Cited by 384

Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair

Feng, Z., Hu, W., Hu, Y., & Tang, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607031103 · Cited by 378

TP53and breast cancer

Børresen‐Dale, A. (2003) · Human Mutation · doi:10.1002/humu.10174 · Cited by 355

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 368

Comparison of the Differential Context-dependence of DNA Deamination by APOBEC Enzymes: Correlation with Mutation Spectra in Vivo

Beale, R. C. L., Petersen‐Mahrt, S. K., Watt, I. N., Harris, R. S., Rada, C. A., & Neuberger, M. S. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.046 · Cited by 340

Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods

Mathé, E. A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj518 · Cited by 340

Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview

Wang, L., Wu, C., Rajasekaran, N., & Shin, Y. K. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495956 · Cited by 360

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer

Stephens, P., Edkins, S., Davies, H. R., Greenman, C., Cox, C., Hunter, C., Bignell, G. R., Teague, J. W., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 333

COSMIC 2005

Forbes, S. A., Clements, J., Dawson, E., Bamford, S., Webb, T., Doǧan, A., Flanagan, A. M., Teague, J. W., Wooster, R., Futreal, P. A., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602928 · Cited by 334

Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer

Tsao, M., Aviel‐Ronen, S., Ding, K., Lau, D., Liu, G., Sakurada, A., Whitehead, M., Zhu, C., Livingston, R. B., Johnson, D. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6953 · Cited by 332

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F. F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 318

Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour

Scott, R. H., Stiller, C. A., Walker, L., & Rahman, N. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.041723 · Cited by 315

The p53 family and programmed cell death

Pietsch, E. C., Sykes, S. M., McMahon, S. B., & Murphy, M. E. (2008) · Oncogene · doi:10.1038/onc.2008.315 · Cited by 331

Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKα kinasesPreprint

Lefort, K., Mandinova, A., Ostano, P., Kolev, V. N., Calpini, V., Kolfschoten, I., Devgan, V., Lieb, J., Raffoul, W., Hohl, D., et al. (2007) · Genes & Development · doi:10.1101/gad.1484707 · Cited by 313

Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription

Chipuk, J. E., Maurer, U., Green, D. R., & Schüler, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00272-1 · Cited by 302

Breast tumor copy number aberration phenotypes and genomic instability

Fridlyand, J., Snijders, A. M., Ylstra, B., Li, H., Olshen, A. B., Segraves, R., Dairkee, S. H., Tokuyasu, T. A., Ljung, B., Jain, A. N., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-96 · Cited by 300

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

Sur, S., Pagliarini, R. A., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 293

Aristolochic Acid and ???Chinese Herbs Nephropathy???

Cosyns, J. (2003) · Drug Safety · doi:10.2165/00002018-200326010-00004 · Cited by 283

Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis

Herceg, Z., & Hainaut, P. L. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.004 · Cited by 296

TheTP53 gene, tobacco exposure, and lung cancer

Toyooka, S., Tsuda, T., & Gazdar, A. F. (2003) · Human Mutation · doi:10.1002/humu.10177 · Cited by 275

TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers

Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0551 · Cited by 273

Mutant p53: an oncogenic transcription factor

Strano, S., Dell’Orso, S., Agostino, S. D., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 272

Mutagenesis at Methylated CpG Sequences

Pfeifer, G. P. (2006) · Springer eBooks · doi:10.1007/3-540-31390-7_10 · Cited by 269

Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia

Langenau, D. M., Feng, H., Berghmans, S., Kanki, J. P., Kutok, J. L., & Look, A. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408708102 · Cited by 259

Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines

Liu, Y., & Bodmer, W. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510146103 · Cited by 257

MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents

Monte, M., Simonatto, M., Peche, L. Y., Bublik, D. R., Gobessi, S., Pierotti, M. A., Rodolfo, M., & Schneider, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510834103 · Cited by 259

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

Hocker, T. L. H., & Tsao, H. (2007) · Human Mutation · doi:10.1002/humu.20481 · Cited by 255

NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma

Galipeau, P. C., Li, X., Blount, P. L., Maley, C. C., Sanchez, C. A., Odze, R. D., Ayub, K., Rabinovitch, P. S., Vaughan, T. L., & Reid, B. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040067 · Cited by 250

Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage

Mahmoudi, S., Henriksson, S., Corcoran, M., Méndez‐Vidal, C., Wiman, K. G., & Farnebo, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.11.027 · Cited by 250

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

Knowles, M. A. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi310 · Cited by 250

Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage

Mahmoudi, S., Henriksson, S., Corcoran, M., Méndez‐Vidal, C., Wiman, K. G., & Farnebo, M. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.01.028 · Cited by 254

Somatic TP53 Mutations in the Era of Genome SequencingPreprint

Hainaut, P. L., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 256

Polymorphisms in the p53 pathway

Pietsch, E. C., Humbey, O., & Murphy, M. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209367 · Cited by 236

Surface plasmon resonance applications in clinical analysis

Mariani, S., & Minunni, M. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7647-5 · Cited by 231

Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D

Hui, L., Zheng, Y., Yan, Y., Bargonetti, J., & Foster, D. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209735 · Cited by 218

Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs

Kitayner, M., Rozenberg, H., Rohs, R., Suad, O., Rabinovich, D., Honig, B. H., & Shakked, Z. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1800 · Cited by 230

Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed

Hicks, S., Wheeler, D. A., Plon, S. E., & Kimmel, M. (2011) · Human Mutation · doi:10.1002/humu.21490 · Cited by 223

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L., Salehi, F., Lin, D., Chung, B. P., Hatfield, G. W., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 226

Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications

Fernández, Y., Verhaegen, M. E., Miller, T. P., Rush, J. L., Steiner, P., Opipari, A. W., Lowe, S. W., & Soengas, M. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0686 · Cited by 220

Regulation of Monocarboxylate Transporter MCT1 Expression by p53 Mediates Inward and Outward Lactate Fluxes in Tumors

Boidot, R., Végran, F., Meulle, A., Breton, A. L., Dessy, C., Sonveaux, P., Lizard‐Nacol, S., & Féron, O. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2474 · Cited by 238

MDM2–p53 Pathway in Hepatocellular Carcinoma

Meng, X., Franklin, D. A., Dong, J., & Zhang, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1446 · Cited by 216

Narrative Review: Protein Degradation and Human Diseases: The Ubiquitin Connection

Reinstein, E., & Ciechanover, A. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00010 · Cited by 216

Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity

Shi, D., & Gu, W. J. (2012) · Genes & Cancer · doi:10.1177/1947601912455199 · Cited by 220

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid

Jelaković, B., Karanović, S., Lela, I. V., Miller, F. W., Edwards, K. L., Nikolić, J., Tomić, K., Slade, N., Brdar, B., Turesky, R. J., et al. (2011) · Kidney International · doi:10.1038/ki.2011.371 · Cited by 214

The role of TP53 in Cervical carcinogenesis

Tommasino, M., Accardi, R., Caldeira, S., Dong, W., Malanchi, I., Smet, A., & Zehbe, I. (2003) · Human Mutation · doi:10.1002/humu.10178 · Cited by 207

Drosophila Checkpoint Kinase 2 Couples Centrosome Function and Spindle Assembly to Genomic Integrity

Takada, S., Kelkar, A., & Theurkauf, W. E. (2003) · Cell · doi:10.1016/s0092-8674(03)00202-2 · Cited by 202

p53 C-Terminal Phosphorylation by CHK1 and CHK2 Participates in the Regulation of DNA-Damage-induced C-Terminal Acetylation

Ou, Y.-H., Chung, P.-H., Sun, T.-P., & Shieh, S.-Y. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0689 · Cited by 211

Nitrative DNA damage in inflammation and its possible role in carcinogenesis

Sawa, T., & Ohshima, H. (2005) · Nitric Oxide · doi:10.1016/j.niox.2005.06.005 · Cited by 198

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging

Ballinger, M. L., Best, A. F., Mai, P. L., Khincha, P. P., Loud, J. T., Peters, J. A., Achatz, M. I., Chojniak, R., da Costa, A. A. B. A., Santiago, K. M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1968 · Cited by 198

Fibrillar Aggregates of the Tumor Suppressor p53 Core Domain

Ishimaru, D., de Andrade, L. R., Teixeira, L. S. P., Quesado, P. A., Maiolino, L. M., Lopez, P. M., Cordeiro, Y., Costa, L. T., Heckl, W. M., Weissmüller, G., et al. (2003) · Biochemistry · doi:10.1021/bi034218k · Cited by 201

p53 Linear Diffusion along DNA Requires Its C Terminus

McKinney, K. M., Mattia, M., Gottifredi, V., & Prives, C. L. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.032 · Cited by 194

Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders

Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00846 · Cited by 190

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

Warso, M. A., Richards, J. M., Mehta, D., Christov, K. T., Schaeffer, C., Bressler, L. R., Yamada, T., Majumdar, D., Kennedy, S., Beattie, C. W., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.74 · Cited by 190

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186

A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma

Salvatore, G., Nappi, T. C., Salerno, P., Jiang, Y., Garbi, C., Ugolini, C., Miccoli, P., Basolo, F., Castellone, M. D., Cirafici, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1887 · Cited by 186

The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers

Olivier, M., Hainaut, P. L., & Petitjean, A. (2007) · IATREIA

IARC TP53 Database

Olivier, M., & Hainaut, P. L. (2008) · Springer eBooks · doi:10.1007/978-3-540-47648-1_2934 · Cited by 1

Untitled work

(1999) · doi:10.1002/(sici)1098-1004(1999)14:1

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation

Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730

Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects

Hainaut, P. L., Soussi, T., Shomer, B., Hollstein, M. C., Greenblatt, M. S., Hovig, E. J., Harris, C. C., & Montesano, R. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.1.151 · Cited by 299